contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-study-confirms-the-strong-efficacy-of-corethermr-in-patients-with-large-prostates

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ProstaLund operates in medical technology. Today, specialisation is mainly in the area of treatment of benign prostate enlargement (BPH). Through the company CoreTherm, heat treatment of benign prostate enlargement is offered, without the need for surgical operation. The vision is to offer both faster and more efficient solutions against traditional forms of infestation. The company was founded in 1991 and is operating globally, based in Lund.

ProstaLund

A newly published Danish study has evaluated the efficacy and safety of CoreTherm® in men with prostate sizes exceeding 100 grams. The median prostate size among participants was 126 g (range...

<div class="mfn-body"><p>A newly published Danish study has evaluated the efficacy and safety of CoreTherm® in men with prostate sizes exceeding 100 grams. The median prostate size among participants was 126 g (range: 101–230 g). The results demonstrate that more than 80% of patients experiencing urinary retention, requiring either an indwelling catheter or self-catheterization, were able to urinate spontaneously at the six-month follow-up after treatment.</p><p>The authors conclude that CoreTherm® provides a satisfactory effect in the majority of treated patients and that the findings suggest that CoreTherm® is a safe and effective treatment option for men with significantly enlarged prostates.</p><p><a rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/39907210/">Reference: Winck-Flyvholm L et al. Transurethral microwave thermotherapy with the CoreTherm®Concept in men with prostates larger than 100 grams – a consecutive case series. Scand J Urol. 2025;60:23-28.</a></p></div><div class="mfn-footer mfn-43458186cf95"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Anders Kristensson,&nbsp;CEO<br>Tel. +46 (0) 769 42 12 16<br>Email: anders.kristensson@prostalund.com</p></div><div class="mfn-footer mfn-3ac97e60f473"><p><strong class="mfn-heading-1">About CoreTherm®</strong></p><hr><p>CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, <a rel="noopener" href="http://www.coretherm.com">www.coretherm.com</a>.</p></div><div class="mfn-footer mfn-about mfn-6fe429febaf6"><p><strong class="mfn-heading-1">About ProstaLund</strong></p><hr><p>ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit <a rel="noopener" href="http://www.prostalund.se">www.prostalund.se</a>. Our press releases are also available to read and download here: <a rel="noopener" href="http://www.prostalund.se/pressmeddelanden">www.prostalund.se/pressmeddelanden</a></p><p><strong>Certified Adviser</strong>:<br>Västra Hamnen Corporate Finance AB<br>Phone: +46 40 200 250<br>E-mail: <a rel="noopener" href="mailto:ca@vhcorp.se">ca@vhcorp.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/1049b635-54f2-4657-920d-3a84b6b749cf/new-study-confirms-the-strong-efficacy-of-coretherm-r-in-patients-with-large-prostates.pdf" class="mfn-generated mfn-primary">New study confirms the strong efficacy of CoreTherm® in patients with large prostates</a></p></div>

New study confirms the strong efficacy of CoreTherm® in patients with large prostates